EBITDA at Rs. 928 crore; Up 29%; and PBT (before exceptional items) at Rs. 183 Cr, Up 153%

ABLE Patron gold member, Biocon Limited has announced its consolidated financial results for the fiscal second quarter ended September 30, 2025.

“Business performance in Q2 FY26 remained strong, with operating revenue up 20% year-on-year to Rs. 4,296 crore, driven by robust growth in Biosimilars, improved momentum in Generics, and a steady contribution from the CRDMO segment. EBITDA grew 29% to Rs. 928 crore, while Profit before Tax (PBT), excluding exceptional items, surged 153% to Rs. 183 crore.

“With the Board approval of the settlement of structured debt obligations, we will strengthen our balance sheet, enhance financial flexibility, and improve profitability. “Our partnership with the State of California through Civica Inc. under the CalRx initiative, marks a landmark step in expanding affordable insulin access in the U.S., with potential to extend to other states. “With a resilient foundation, differentiated portfolio, and clear strategy, we are well positioned to sustain growth and deliver long-term value to our stakeholders,” said Dr Kiran Mazumdar-Shaw, Chairperson, Biocon Group.

Biocon Generics

“The Generics business continued its steady performance in Q2 with a growth of 24% driven primarily by an uptick in recently launched products in the U.S. and EU, as well as growth in the generic formulations base business, and the API business.

“A key highlight of this quarter was the inauguration of Biocon’s first OSD manufacturing facility in the United States, a significant step towards expanding access to our vertically 

integrated portfolio for patients in the region. We commenced filings for Semaglutide (gOzempic) in various markets, including Canada and Brazil,” commented Mr Siddharth Mittal, CEO & Managing Director, Biocon Limited

Biocon Biologics

“Biocon Biologics delivered a strong performance in Q2 FY26, achieving 25% year-on-year revenue growth and an over 40% increase in EBITDA. Sequentially, revenues grew 11%, driven by market share expansion in key therapy areas and successful new product launches.

In the U.S., we continue to expand access to biosimilars by leveraging the strength of our commercial platform. In FY26, we launched four biosimilars across key global markets and remain on track for the bDenosumab launch,” said Dr Shreehas Tambe, CEO & Managing Director, Biocon Biologics Limited.

Syngene International

“Our Q2 results reflect strong underlying revenue growth in research services, which has offset the expected inventory correction in biologics manufacturing. We continue to maintain our annual guidance for FY26.

“We are also building a GMP bioconjugation suite at our Bengaluru biologics facility, which will enable end-to-end manufacturing of Antibody Drug Conjugates (ADCs), positioning us among a select group of CRDMOs offering comprehensive ADC services,” commented Mr Peter Bains, CEO & Managing Director, Syngene International Limited.

“With a resilient foundation, differentiated portfolio, and clear strategy, we are well positioned to sustain growth and deliver long-term value to our stakeholders,” said Dr Kiran Mazumdar-Shaw, Chairperson, Biocon Group.